Safety Study of a Liposomal Vaccine to Treat Malignant Melanoma
The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
Melanoma
BIOLOGICAL: Lipovaxin-MM
Adverse events, Within 84 days after first dose|Immunogenicity, antigen specific immune responses will be monitored, Within 42 days of first dose
Anti-cancer activity (RECIST criteria), assessed every 6 weeks of study, Within 84 days of first dose
The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.